Orchard Therapeutics Strengthens Commercial Leadership Team with Appointment of Francis Pang as Vice President of Global Market Access
BOSTON and LONDON,
“Francis brings deep expertise and innovative thinking in the area of market access and reimbursement within our industry and has been recognized by the
Mr. Pang has more than 20 years of experience in pricing and reimbursement, market access and health economics. Most recently, Mr. Pang was global head of market access at
Prior to his work in the biopharmaceutical industry, Mr. Pang was the inaugural Pharmacoeconomics Research Fellow at the
About Orchard
Orchard’s portfolio of autologous, ex vivo, hematopoietic stem cell gene therapies includes Strimvelis, a gammaretroviral vector-based gene therapy and the first such treatment approved by the
Orchard currently has offices in the U.K. and the U.S., including
Forward-Looking Statements
This press release contains certain forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, planned commercialization readiness efforts in anticipation of future regulatory achievements. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, without limitation: the risk that any one or more of Orchard’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any of Orchard’s ongoing or planned clinical trials, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchard’s product candidates, and the risk of delays in Orchard’s ability to commercialize its product candidates, if approved. Orchard undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. For additional disclosure regarding these and other risks faced by Orchard, see the disclosure contained in Orchard’s public filings with the Securities and Exchange Commission.
Contact:
+1 862-242-0764
Renee.Leck@orchard-tx.com
Source: Orchard Therapeutics Limited